Impact of post-resistance molecular retesting strategies on treatment timeliness and clinical outcomes in EGFR-mutant advanced NSCLC: a real-world study
To evaluate the association of ctDNA-based molecular retesting with treatment timeliness and clinical outcomes in patients with advanced EGFR-mutant NSCLC after first-line EGFR-TKI resistance. We retrospectively analyzed patients with advanced EGFR-mutant NSCLC who had radiologically confirmed progression af...